Literature DB >> 22064687

The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial.

Julie M Bakobaki1, Mary Rauchenberger, Nicola Joffe, Sheena McCormack, Sally Stenning, Sarah Meredith.   

Abstract

BACKGROUND: Compliance with Good Clinical Practice (GCP) guidelines should ensure the safety of trial participants and the reliability of trial results. Over the last decade, increasing emphasis has been placed on the role of costly on-site monitoring and source data verification as processes to demonstrate that GCP is being followed, despite a lack of empirical evidence that these are effective.
PURPOSE: To assess whether findings from on-site monitoring of a recent international multi-centre clinical trial could have been identified using central data review and other centralised monitoring techniques.
METHODS: Findings documented in a sample of site monitoring reports, and Programme Management Board Executive (PMBe) reports, from the Microbicides Development Programme (MDP) 301 trial - a randomised placebo-controlled trial of a microbicide gel to prevent vaginally acquired HIV infection conducted in four countries in East and Southern Africa - were extracted and individually assessed to determine whether they could have been detected in the trial database or through other central means.
RESULTS: Four site visit reports contained 268 monitoring findings from a review of 104 participant files covering 324 study visits. Of the 268 findings, 76 (28.4%) were also identified in the study database. Central checks, had these been in place (such as central receipt and review of back-translated documents, enrolment and testing logs, informed consent, and more complex database queries), could have identified a further 179 (66.8%); 13 (4.9%) other findings (all minor) could have been identified through a review of the participant folder at site. The four PMBe reports reviewed included six major and three critical findings from a review of over 1000 participant files: only two of these (both major) were assessed as unlikely to be identified using central monitoring techniques. LIMITATIONS: The study data used were not collected with this retrospective review in mind. It suggests that prospective work is needed to compare monitoring practices in real time.
CONCLUSIONS: While there may be some categories of findings that it is not possible to identify centrally, the very large majority of findings reviewed in this analysis could be identified using central monitoring strategies. These data suggest that with better central and targeted on-site monitoring, it should be possible to identify and address most protocol and procedural compliance issues without performing intensive and costly routine on-site data monitoring.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22064687     DOI: 10.1177/1740774511427325

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  23 in total

Review 1.  Data-driven risk identification in phase III clinical trials using central statistical monitoring.

Authors:  Catherine Timmermans; David Venet; Tomasz Burzykowski
Journal:  Int J Clin Oncol       Date:  2015-08-02       Impact factor: 3.402

2.  Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial.

Authors:  Catherine Timmermans; Erik Doffagne; David Venet; Lieven Desmet; Catherine Legrand; Tomasz Burzykowski; Marc Buyse
Journal:  Gastric Cancer       Date:  2015-08-23       Impact factor: 7.370

Review 3.  The impact of clinical trial monitoring approaches on data integrity and cost--a review of current literature.

Authors:  Rasmus Olsen; Asger Reinstrup Bihlet; Faidra Kalakou; Jeppe Ragnar Andersen
Journal:  Eur J Clin Pharmacol       Date:  2016-01-04       Impact factor: 2.953

4.  Data fraud in clinical trials.

Authors:  Stephen L George; Marc Buyse
Journal:  Clin Investig (Lond)       Date:  2015

5.  Clinical Monitoring in a Federally Funded Environment: Evolution and Opportunities in the Cardiovascular Cell Therapy Research Network.

Authors:  Sibi R Mathew; Kristen D Lucas; Shelly L Sayre; Judy Bettencourt; Tina Collins; Dana Leach; Rachel E Olson; Doris A Taylor; Lemuel Moyé
Journal:  Monitor (Assoc Clin Pharmacol)       Date:  2014-02

6.  Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials.

Authors:  Jeppe Ragnar Andersen; Inger Byrjalsen; Asger Bihlet; Faidra Kalakou; Hans Christian Hoeck; Gitte Hansen; Henrik Bo Hansen; Morten Asser Karsdal; Bente Juel Riis
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

Review 7.  Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

Authors:  Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; Eric G Devine; David Hewitt; Mark P Jensen; Nathaniel P Katz; Amy A Kirkwood; Richard Malamut; John D Markman; Bernard Vrijens; Laurie Burke; James N Campbell; Daniel B Carr; Philip G Conaghan; Penney Cowan; Mittie K Doyle; Robert R Edwards; Scott R Evans; John T Farrar; Roy Freeman; Ian Gilron; Dean Juge; Robert D Kerns; Ernest A Kopecky; Michael P McDermott; Gwendolyn Niebler; Kushang V Patel; Richard Rauck; Andrew S C Rice; Michael Rowbotham; Nelson E Sessler; Lee S Simon; Neil Singla; Vladimir Skljarevski; Tina Tockarshewsky; Geertrui F Vanhove; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2019-12-13       Impact factor: 5.820

Review 8.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

9.  Ensuring participant safety and trial integrity with clinical trials oversight.

Authors:  Catherine Godfrey; Manizhe Payton; Sybil Tasker; Scott Proestel; Jeffrey T Schouten
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

10.  Exploring Data Quality Management within Clinical Trials.

Authors:  Lauren Houston; Yasmine Probst; Ping Yu; Allison Martin
Journal:  Appl Clin Inform       Date:  2018-01-31       Impact factor: 2.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.